JY
GLUE icon

Jeff Yass’s Monte Rosa Therapeutics GLUE Stock Holding History

Jeff Yass’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
43,100
+16,600
+63% +$314K ﹤0.01% 8097
2026
Q1 		$436K Sell
26,500
-136,200
-84% -$2.6M ﹤0.01% 10008
2025
Q4 		$2.55M Sell
162,700
-9,300
-5% -$125K ﹤0.01% 5163
2025
Q3 		$1.27M Buy
+172,000
New +$911K ﹤0.01% 6751
2024
Q3 		– Sell
-12,100
Closed -$45.3K – 12361
2024
Q2 		$45.3K Buy
12,100
+700
+6% +$3.57K ﹤0.01% 11456
2024
Q1 		$80.4K Sell
11,400
-73,200
-87% -$434K ﹤0.01% 11334
2023
Q4 		$478K Buy
+84,600
New +$332K ﹤0.01% 8779

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's GLUE Position: Q2 2026 in Review

Jeff Yass increased its Monte Rosa Therapeutics (GLUE) stake by 39% in Q2 2026, buying an estimated $180K and bringing the position to 34,281 shares worth $830K. The position accounts for ﹤0.01% of the portfolio, ranked #8680.

Jeff Yass first reported a position in GLUE in Q2 2022 and has held it in 11 quarters since. 191 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Jeff Yass held 34,281 shares of Monte Rosa Therapeutics worth $830K as of Q2 2026.
  • Jeff Yass bought 9,530 Monte Rosa Therapeutics shares in Q2 2026, an estimated $180K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8680 holding.
  • Jeff Yass first reported a position in Monte Rosa Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.